文献速递瓣膜外科

微创二尖瓣手术与优异的资源利用、成本和结局相关

Minimally invasive mitral valve surgery is associated with excellent resource utilization, cost, and outcomes.
PubMed 文献 · J Thorac Cardiovasc Surg · 2018-04-03

该研究将2011至2016年二尖瓣手术记录与院内财务记录配对,按手术方式分层并行倾向性评分匹配。匹配后每组74例,微创二尖瓣手术(mini-MVR)的主要并发症发生率与常规手术相似,输血率和呼吸机使用时间更低,总体住院费用相当;微创手术的外科和植入物费用更高,被输血及辅助费用下降所抵消。

要点

  • 匹配后每组74例,微创二尖瓣手术与常规手术的主要并发症发生率相似(9.5% vs 10.8%,P = .78)。
  • 微创二尖瓣手术输血率更低(11% vs 27%,P = .01),呼吸机使用时间更短(3.7 vs 6.0小时,P < .0001)。
  • 平均总住院费用相当(49,703美元 vs 54,970美元,P = .235),微创手术辅助费用和血液费用更低,但外科和植入物费用更高。

核心结论

  • 在真实世界队列中,微创二尖瓣手术持续显示出优异结果和有利的资源利用特征。
  • 微创二尖瓣手术较高的外科和植入物费用被输血及辅助需求下降所抵消,总体住院费用相当。

研究设计与样本

  • 研究将2011至2016年二尖瓣手术记录与院内财务记录配对,按手术方式分层并行倾向性评分匹配以平衡术前差异。
  • 共478例患者接受二尖瓣手术(21%为微创二尖瓣手术),匹配后每组74例,18%的患者为非退行性二尖瓣疾病。

主要发现

  • 主要并发症发生率微创二尖瓣手术组9.5% vs 常规手术组10.8%(P = .78)。
  • 输血率微创二尖瓣手术组11% vs 常规手术组27%(P = .01),呼吸机使用时间微创二尖瓣手术组3.7小时 vs 常规手术组6.0小时(P < .0001)。
  • 平均总住院费用微创二尖瓣手术组49,703美元 vs 常规手术组54,970美元(P = .235),辅助费用1645美元 vs 2652美元(P = .001),血液费用383美元 vs 1058美元(P = .001)。
  • 手术时间微创二尖瓣手术组291分钟 vs 常规手术组234分钟(P < .0001),外科费用7645美元 vs 7293美元(P = .0001),植入物费用1148美元 vs 748美元(P = .03)。
  • 转运至机构率微创二尖瓣手术组9.6% vs 常规手术组16.2%,再入院率9.6% vs 4.1%,均无统计学差异。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Minimally invasive mitral valve surgery (mini-MVR) has numerous associated benefits. However, many studies fail to include greater-risk patients. We hypothesized that a minimally invasive approach in a representative cohort provides excellent outcomes with reduced resource utilization. METHODS: Mitral valve surgical records from 2011 to 2016 were paired with institutional financial records. Patients were stratified by approach and propensity-score matched to balance preoperative difference. The primary outcomes of interest were resource utilization including cost, discharge to a facility, and readmission. RESULTS: A total of 478 patients underwent mitral surgery (21% mini-MVR) and were balanced after matching (n = 74 per group), with 18% of patients having nondegenerative mitral disease. Outcomes were excellent with similar rates of major morbidity (9.5% mini-MVR vs 10.8% conventional, P = .78). Mini-MVR cases had lower rates of transfusion (11% vs 27%, P = .01) and shorter ventilator times (3.7 vs 6.0 hours, P < .0001). Mean total hospital cost was equivalent ($49,703 vs $54,970, P = .235) with mini-MVR having lower ancillary ($1645 vs $2652, P = .001) and blood costs ($383 vs $1058, P = .001). These savings were offset by longer surgical times (291 vs 234 minutes, P < .0001) with greater surgical ($7645 vs $7293, P = .0001) and implant costs ($1148 vs $748, P = .03). Rates of discharge to a facility (9.6% vs 16.2%) and readmission (9.6% vs 4.1%) were not statistically different. CONCLUSIONS: In a real-world cohort, mini-MVR continues to demonstrate excellent results with a favorable resource utilization profile. Greater surgical and implant costs with mini-MVR are offset by decreased transfusions and ancillary needs leading to equivalent overall hospital cost.

来源:J Thorac Cardiovasc Surg,查看原文。版权归原作者所有。

引用

  1. Hawkins RB, Mehaffey JH, Kessel SM, et al. Minimally invasive mitral valve surgery is associated with excellent resource utilization, cost, and outcomes. J Thorac Cardiovasc Surg. 2018. PMID: 29709359. doi:10.1016/j.jtcvs.2018.03.108

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。